

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)



(10) International Publication Number
WO 2025/101982 A1

(51) International Patent Classification:

A61P 43/00 (2006.01) *C07K 16/28* (2006.01)
C07K 16/42 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:

PCT/US2024/055240

(22) International Filing Date:

08 November 2024 (08.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/597,777 10 November 2023 (10.11.2023) US
63/712,818 28 October 2024 (28.10.2024) US

(71) Applicants: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001 (US). **BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON** [US/US]; 1201 9th Avenue, Seattle, Washington 98101 (US).

(72) Inventors: **FRANKLIN, Edward Michael**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondlkin, Dublin, D22 V8F8 (IE). **FENNELL, Brian Joseph**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondlkin, Dublin, D22 V8F8 (IE). **STACK, Edwina Catherine**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondlkin, Dublin, D22 V8F8 (IE). **MOSYAK, Lidia**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **APGAR, James Reasoner**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **CHABOT, Jeffrey Raymond**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **KHOR, Bernard**; c/o Benaroya Research Institute at Virginia Mason, 1201 9th Avenue, Room 270, Seattle, Washington 98101 (US). **MIKITA, Thomas Jay**; 33 East Pier, Sausalito, California 94965 (US). **CHAPARRO-RIGGERS, Javier Fernando**; c/o Pfizer Inc., 10724 Science Center Dr., San Diego, California 92121 (US).

(74) Agent: **GUMMOW, Brian M.** et al.; Haley Guiliano LLP, 75 Broad Street, Suite 1000, New York, New York 10004 (US).

(54) Title: ANTI-MIGIS-ALPHA ANTIBODIES AND METHODS OF USE THEREOF




FIG. 6

(57) Abstract: Provided herein are antibodies (including antigen-binding fragments thereof) that specifically bind to MIGIS-alpha, including for example without limitation, bispecific MIGIS-alpha/CD3 antibodies, other related antibodies, related nucleic acids, uses, and associated methods thereof. The disclosure also provides processes for making, preparing, and producing antibodies disclosed herein, including antibodies that bind to one or both of MIGIS-alpha and CD3.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))